Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
- Conditions
- Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
- First Posted Date
- 2018-01-24
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT03409081
- Locations
- 🇦🇺
Site AU61001, Canberra, Australia
🇮🇹Site IT39001, Milan, Italy
🇮🇹Site IT39003, Milan, Italy
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- Drug: Sham
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT03364153
- Locations
- 🇺🇸
Retinal Research Institute, Phoenix, Arizona, United States
🇺🇸Jules Stein Eye Institute/ David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸VitreoRetinal Associates, Gainesville, Florida, United States
A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03356639
- Locations
- 🇺🇸
Cctmg/Parexel, Glendale, California, United States
🇺🇸Community Clinical Research, Austin, Texas, United States
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
- Conditions
- Renal Pelvis NeoplasmsCarcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic NeoplasmsUrothelial CancerUreteral NeoplasmsUrethral Neoplasms
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 348
- Registration Number
- NCT03288545
- Locations
- 🇺🇸
Alaska Urological Institute, Anchorage, Alaska, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT03260322
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
- Conditions
- Hematological Malignancy
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03241550
- Locations
- 🇺🇸
Miller Children's Hospital, Long Beach, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸CHOC Children's Hospital of Orange County, Orange, California, United States
A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 356
- Registration Number
- NCT03192176
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
🇺🇸Research Site 052, Sacramento, California, United States
🇺🇸Research Site 058, Sacramento, California, United States
A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT03092726
- Locations
- 🇺🇸
Noesis Pharma, LLC, Phoenix, Arizona, United States
🇺🇸Excell Research, Inc, Oceanside, California, United States
🇺🇸Collaborative Neuroscience Network, LLC., Torrance, California, United States
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
- Conditions
- Non-small Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor (EGFR) Mutations
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03082300
- Locations
- 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸Renovatio Clinical, The Woodlands, Texas, United States
🇺🇸US Oncology - Virginia Cancer Specialists, P.C. (VCS), Fairfax, Virginia, United States
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
- Conditions
- Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT03070093
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Rocky Mountain Cancer Center-M, Aurora, Colorado, United States
🇺🇸Memorial Healthcare System, Pembroke Pines, Florida, United States